Navigation Links
Multitarget TB drug could treat other diseases, evade resistance
Date:4/17/2014

hat some of the enzymes that we study as cancer and antiparasitic drug targets also could be SQ109 targets. We hoped that we could make some analogs that would be more potent against tuberculosis, and maybe even against parasites."

By studying SQ109 for themselves, Oldfield's team determined that SQ109 does indeed block other proteins involved in critical functions in bacteria, fungi and parasites but not humans. They found it inhibits two enzymes that make the molecule menaquinone, which is involved in generating the cell's energy. Then they found that SQ109 had a third action, called uncoupling, which makes the cell membrane permeable essentially transforming the membrane from a wall to a screen door.

Then, the team created a dozen chemical analogs molecules that are structurally and functionally similar, but tweaked to be more effective or less toxic and tested them against cultures of bacteria, fungi, parasites and human cells. They found that they could make analogs with maximum effectiveness against certain classes of pathogens; for example, one analog turned out to be five times more potent against the tuberculosis bacterium than the original SQ109. They also found analogs that kill the parasites that cause the most serious and common form of malaria.

Now, the researchers are working with international collaborators to apply SQ109 analogs against other infectious diseases rampant in the tropical world, such as Chagas' disease, leishmaniasis and sleeping sickness.

Oldfield believes that multiple-target drugs, like SQ109 and its analogs, hold the key to antibiotic development in the age of drug resistance and the rise of so-called "superbugs." Evidence supports that assessment: So far, in experiments with tuberculosis, no instances of SQ109 resistance have been reported.


'/>"/>

Contact: Liz Ahlberg
eahlberg@illinois.edu
217-244-1073
University of Illinois at Urbana-Champaign
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Heart-powered pacemaker could one day eliminate battery-replacement surgery
2. New test could help track down and prosecute terrorists
3. New antibiotic could make food safer and cows healthier
4. BPA could affect reproductive capabilities, cause infection of the uterus
5. Key to immune system disease could lie inside the cheek
6. New analysis of premature infants heartbeats, breathing could be cues for leaving NICU
7. Tiny electrical sensors could signal faster MRSA diagnosis
8. Corals could survive a more acidic ocean
9. Early warning system for seizures could cut false alarms
10. Rapid method of assembling new gene-editing tool could revolutionize genetic research
11. 800-year-old farmers could teach us how to protect the Amazon
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Multitarget TB drug could treat other diseases, evade resistance
(Date:12/3/2014)... , Dec. 2, 2014   Marvin ... deployed, innovative test solutions for military, aerospace, and ... version of its successful TS-900 PXI semiconductor ... and features of high-end systems to customers at ... value compared to traditional ATE. ...
(Date:11/21/2014)... , Nov. 20, 2014 Strict laws against ... are piloting the North American and European automotive sector ... growing, gesture recognition systems that are intuitive and able ... in the industry. New analysis from ... Recognition Market in Europe and ...
(Date:11/18/2014)...   News Highlights: ... The Partners Data Lake, an agile data and ... will allow researcher and clinicians to explore and ... lives of patients , The Partners Data ... the Partners system, breaking down physical barriers for ...
Breaking Biology News(10 mins):Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5
... vital component of good health. Like plants that thrive in ... case for the production of vitamin D. In the past ... sun exposure. From fear of the potential dangers of UV ... work and recreational environments centered on virtual reality, we are ...
... 19 March 2009 World Water Day on Sunday, ... increasing scarcity of clean drinking water on our planet. ... causing more damage than ever before. Helmholtz scientists ... on solutions to precisely these problems. In cooperation with ...
... for Science Writings at Stevens Institute of Technology will host ... a talk by Bernd Heinrich, on Wednesday, April 1, 2009. ... 122, from 4 p.m. to 5:30 p.m. The journalist ... naturalist writer; he,s a great writer, period." A professor emeritus ...
Cached Biology News:The sunlight solution for better health 2The sunlight solution for better health 3Research to secure a safe water supply 2Research to secure a safe water supply 3Research to secure a safe water supply 4
(Date:12/24/2014)... (PRWEB) December 24, 2014 The report ... at 19.7% by 2019. It also provides a carefully ... strategies and challenges for the market. , Full Copy ... the report, the global market for cell expansion will ... future. It expects this growth to be driven by ...
(Date:12/24/2014)... AUSTIN, Texas , Dec. 23, 2014 /PRNewswire/ ... solutions company focused on gynecologic disease, announced today ... W. Schuler , Birchview Fund LLC and several ... million of unregistered shares of Vermillion,s common stock ... common stock in a private placement.  ...
(Date:12/24/2014)... SARASOTA, Fla. , Dec. 23, 2014  Rock ... today that it has filed a Clinical Trial Application ... Medicines Healthcare products Regulatory Agency (MHRA) seeking regulatory approval ... its lead molecule, Anatabine Citrate. Contingent on ... to conduct a Phase I trial to assess the ...
(Date:12/22/2014)... Md. , Dec. 22, 2014 /PRNewswire/ ... SYN), a developer of pathogen-specific therapies for ... on protecting the microbiome, today announced positive ... Phase 1a clinical trial of SYN-004, the ... prevention of Clostridium difficile (C. difficile) ...
Breaking Biology Technology:The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... 16 Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that ... with Abbott for the exclusive worldwide development and commercialization of elagolix and the ... , The live ... at 8:45 a.m. Eastern Time ( 5:45 a.m. Pacific Time ...
... ... for certifying dentists in a new denture retention system procedure that can add 20% profit to ... (PRWEB) June 16, ... in a new denture retention system procedure that can add 20% profit to a ...
... American ... ... Association named medical writer, Rita Buckley, Writer/Owner of medical writing firm Buckley/Swartz, ... the awards for The Lehman Series Expert Panel on Weight Loss Surgery, published in ...
Cached Biology Technology:Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix 2Summit Dental Institute Offers A Hands-On One-Day Imtec MDI Mini Dental Implant Certification Course For Dentists 2Summit Dental Institute Offers A Hands-On One-Day Imtec MDI Mini Dental Implant Certification Course For Dentists 3Summit Dental Institute Offers A Hands-On One-Day Imtec MDI Mini Dental Implant Certification Course For Dentists 4Medical Writer Rita Buckley Wins Awards for Excellence in Medical Communication 2Medical Writer Rita Buckley Wins Awards for Excellence in Medical Communication 3
... a chromogenic medium for the detection, ... (except S. thyphi) and total coliforms ... takes a maximum of 24 hours, ... sterilization during preparation and performs a ...
Large-capacity refrigerated incubator chamber holds up to 4 independently-operated shakers. Programmable heat, refrigeration, humidifcation are standard. Photosynthetic operation, optional....
...
... The Pulsed Dynamic Focusing MALDI (PDF-MALDI) source ... samples that do not need online separation. ... Trap LC/MS and Agilents powerful Spectrum Mill ... fast analysis of 2D gel-spot digests. It ...
Biology Products: